BR112016007329A2 - composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1 - Google Patents

composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1

Info

Publication number
BR112016007329A2
BR112016007329A2 BR112016007329A BR112016007329A BR112016007329A2 BR 112016007329 A2 BR112016007329 A2 BR 112016007329A2 BR 112016007329 A BR112016007329 A BR 112016007329A BR 112016007329 A BR112016007329 A BR 112016007329A BR 112016007329 A2 BR112016007329 A2 BR 112016007329A2
Authority
BR
Brazil
Prior art keywords
hsf1
disease
treating
compound
pharmaceutical composition
Prior art date
Application number
BR112016007329A
Other languages
English (en)
Other versions
BR112016007329B1 (pt
Inventor
Elisa Pasqua Adele
Rye Carl
Jones Keith
Gordon Pike Kurt
Cheeseman Matthew
Chessum Nicola
Frank Faulder Paul
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of BR112016007329A2 publication Critical patent/BR112016007329A2/pt
Publication of BR112016007329B1 publication Critical patent/BR112016007329B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

a presente invenção se refere a compostos da fórmula i em que a1, a2, r4 e q são conforme aqui definido. os compostos da presente invenção são inibidores de fator de choque térmico 1 (hsf1). em particular, a presente invenção se refere ao uso destes compostos como agentes terapêuticos por o tratamento e/ou prevenção de doenças proliferativas, tal como câncer. a presente invenção também se refere a processos para a preparação destes compostos, e às composições farmacêuticas compreendendo-os.
BR112016007329-0A 2013-10-04 2014-10-03 composto, composição farmacêutica, e, uso de um composto para manufatura de um medicamento para tratamento de câncer, doenças autoimunes ou doenças virais BR112016007329B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1317609.4 2013-10-04
GBGB1317609.4A GB201317609D0 (en) 2013-10-04 2013-10-04 Inhibitor compounds
PCT/GB2014/052992 WO2015049535A1 (en) 2013-10-04 2014-10-03 Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1

Publications (2)

Publication Number Publication Date
BR112016007329A2 true BR112016007329A2 (pt) 2017-08-01
BR112016007329B1 BR112016007329B1 (pt) 2021-02-02

Family

ID=49630211

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007329-0A BR112016007329B1 (pt) 2013-10-04 2014-10-03 composto, composição farmacêutica, e, uso de um composto para manufatura de um medicamento para tratamento de câncer, doenças autoimunes ou doenças virais

Country Status (21)

Country Link
US (4) US9701664B2 (pt)
EP (2) EP3052492B1 (pt)
JP (2) JP6500017B2 (pt)
KR (1) KR102332232B1 (pt)
CN (1) CN105814040B (pt)
AU (1) AU2014330940B2 (pt)
BR (1) BR112016007329B1 (pt)
CA (1) CA2925182C (pt)
DK (2) DK3521286T3 (pt)
ES (2) ES2902124T3 (pt)
GB (1) GB201317609D0 (pt)
HK (1) HK1224285A1 (pt)
IL (1) IL244452B (pt)
MX (1) MX369952B (pt)
PL (2) PL3521286T3 (pt)
PT (2) PT3052492T (pt)
RU (1) RU2671979C2 (pt)
SG (1) SG11201602547PA (pt)
TR (1) TR201908265T4 (pt)
WO (1) WO2015049535A1 (pt)
ZA (1) ZA201601223B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) * 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
WO2018162312A1 (en) 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
EP3679028A1 (en) * 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones
WO2019133574A2 (en) * 2017-12-26 2019-07-04 Southern Research Institute Benzoannulene derivatives as antiviral agents
EP4045502A1 (de) * 2019-10-17 2022-08-24 Bayer Aktiengesellschaft Photochemisches verfahren zur herstellung von (4r, 4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid
WO2023057819A1 (en) 2021-10-06 2023-04-13 Institute Of Cancer Research Methods of treating cancer using hsf1 pathway inhibitors
WO2023111005A1 (en) 2021-12-14 2023-06-22 Wmt Ag Carboxamide substituted heteroaromatic compounds for treating cancer
WO2023194458A1 (en) 2022-04-05 2023-10-12 Wmt Ag N-(3-(benzo[b]thiophene-2-carboxamido)-phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide derivatives and related compounds as lactate/atp production inhibitors for the treatment of cancer

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137805A (en) 1988-03-18 1992-08-11 The General Hospital Corporation Method of diagnosing stress condition by specific binding of human heat shock factor
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
JP2845623B2 (ja) 1990-11-26 1999-01-13 アメリカ合衆国 細胞のストレス転写因子
DE19531321A1 (de) 1995-08-25 1997-02-27 Merck Patent Gmbh Piperidinylmethyloxazolidinone
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US7053052B2 (en) 1997-01-21 2006-05-30 Voellmy Richard W Therapies involving mutated heat shock transcription factor
AU7933298A (en) * 1997-06-27 1999-01-19 Kaneka Corporation Heat shock factor activity inhibitors
BR9814327A (pt) 1997-12-23 2000-10-03 Warner Lambert Co Compostos de tiouréia e benzamida, composições e pro-cessos para tratamento ou prevenção de doenças infla-matórias e arteriosclerose
CN1185211C (zh) 1998-05-15 2005-01-19 阿斯特拉曾尼卡有限公司 用于治疗由细胞活素引起的疾病的苯甲酰胺衍生物
US6432949B1 (en) 1998-08-04 2002-08-13 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
ATE254105T1 (de) 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
PT1163237E (pt) 1999-03-17 2004-08-31 Astrazeneca Ab Derivados de amida
CA2366877A1 (en) 1999-03-22 2000-09-28 Stanley Michael Roberts Chemical compounds and their uses
US6867036B1 (en) 1999-11-23 2005-03-15 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
US7405080B2 (en) 2000-03-23 2008-07-29 Voellmy Richard W Compositions and methods relating to prevention of chemotherapy-induced alopecia
CN100400518C (zh) 2000-10-30 2008-07-09 库多斯药物有限公司 2,3-二氮杂萘酮衍生物
ATE367806T1 (de) 2001-09-03 2007-08-15 Richard Voellmy Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie
AU2003281198A1 (en) 2002-07-04 2004-01-23 Mitsui Chemicals, Inc. m-PHENYLENEDIAMINE DERIVATIVE
NZ537858A (en) 2002-07-15 2008-04-30 Myriad Genetics Inc Compounds, compositions, and methods employing same
GB0218260D0 (en) 2002-08-06 2002-09-11 Charterhouse Therapeutics Ltd Improvements in pharmaceutically useful compounds
US20050113450A1 (en) 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
CA2497240A1 (en) 2002-08-29 2004-03-11 Andrew Asher Protter Methods of promoting osteogenesis
CA2497951A1 (en) 2002-09-05 2004-03-18 Scios Inc. Treatment of pain by inhibition of p38 map kinase
AU2003272327A1 (en) 2002-09-11 2004-04-30 University Of Medicine And Dentistry Of New Jersey Methods of bone healing
GB0223696D0 (en) 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
CA2510471A1 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
CA3084542A1 (en) 2003-06-10 2005-01-06 The Trustees Of Boston University Gene expression analysis of airway epithelial cells for diagnosing lung cancer
RU2006104697A (ru) 2003-07-16 2006-06-27 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. (Jp) Лекарственное средство для лечения пигментации кожи
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
WO2005042496A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-benzyl-amine derivatives and methods for inhibiting heparanase activity
US7427390B2 (en) 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
WO2006040568A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as b raf inhibitors
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
US20090062222A1 (en) 2005-09-29 2009-03-05 Trustees Of Boston University Methods for Sensitizing Cancer Cells to Inhibitors
US8101610B2 (en) 2005-11-14 2012-01-24 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
EP1830289A1 (en) 2005-11-30 2007-09-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for hepatocellular carninoma classification and prognosis
US7919603B2 (en) 2005-12-19 2011-04-05 New York University Heat shock RNA
JP5296688B2 (ja) 2006-09-11 2013-09-25 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 殺虫化合物
WO2008079269A2 (en) 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US8518649B2 (en) 2007-04-04 2013-08-27 {hacek over (S)}árka O. Southern Systems and methods for analyzing persistent homeostatic perturbations
CA2690569A1 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
CN101896461A (zh) 2007-12-13 2010-11-24 安姆根有限公司 γ分泌酶调节剂
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009137796A2 (en) 2008-05-08 2009-11-12 Northwestern University Method of regulating the heat shock response
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CA2725963A1 (en) 2008-06-03 2009-12-10 Cytrx Corporation Screening methods for heat-shock response modulators
KR20110036056A (ko) 2008-06-26 2011-04-06 다나-파버 캔서 인스티튜트 인크. 전이와 관련된 시그너처 및 결정인자 및 이의 사용 방법
UA38601U (en) * 2008-07-17 2009-01-12 Львовский Национальный Медицинский Университет Имени Данилы Галицкого 2,2'-dithioxo-4,4'-dioxo-[5,5']-bithiazolidinyl-idene-diyl-3,3'-dibutanoic acid diarylamides having antitumor activity
EP2344876A4 (en) 2008-10-02 2012-05-09 Gaia Medical Inst HEALTH TEST FOR A WIDE SPECTRUM OF HEALTH PROBLEMS
EP2367545A1 (en) 2008-10-17 2011-09-28 Université Libre de Bruxelles Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy
WO2010053655A2 (en) 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
CA2746506A1 (en) 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
US8637532B2 (en) 2009-02-11 2014-01-28 Merck Patent Gmbh Amino azaheterocyclic carboxamides
KR101630432B1 (ko) 2009-08-28 2016-06-15 한국생명공학연구원 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
AR079494A1 (es) 2009-12-18 2012-02-01 Novartis Ag Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1
US20130133108A1 (en) 2010-08-25 2013-05-23 Katherine Warpeha Extracts from pirin+ and pirin- plants and uses thereof
US9746470B2 (en) 2011-05-09 2017-08-29 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
WO2013006495A2 (en) 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
MX2014002536A (es) 2011-09-02 2014-09-01 Novartis Ag Composiciones organicas para tratar enfermedades relacionadas con el factor de choque de calor 1 (hsf1).
US9696313B2 (en) 2011-10-06 2017-07-04 Whitehead Institute For Biomedical Research HSF1 as a marker in tumor prognosis and treatment
EP2877859A4 (en) 2012-05-03 2016-08-03 Whitehead Biomedical Inst HSF1 AND HSF1 CSS GENES AND USES THEREOF
KR101507221B1 (ko) 2012-05-14 2015-03-31 이화여자대학교 산학협력단 두충으로부터 분리된 화합물을 포함하는 열충격단백질 유도 활성을 갖는 조성물
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
GB201317609D0 (en) * 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound

Also Published As

Publication number Publication date
CN105814040B (zh) 2019-07-30
EP3521286B1 (en) 2021-09-29
PL3052492T3 (pl) 2019-09-30
SG11201602547PA (en) 2016-04-28
RU2016117056A (ru) 2017-11-10
ES2902124T3 (es) 2022-03-25
EP3052492B1 (en) 2019-03-27
RU2671979C2 (ru) 2018-11-08
DK3521286T3 (da) 2021-12-06
JP2016531891A (ja) 2016-10-13
EP3052492A1 (en) 2016-08-10
ZA201601223B (en) 2020-08-26
CA2925182A1 (en) 2015-04-09
CA2925182C (en) 2022-10-04
US11787786B2 (en) 2023-10-17
TR201908265T4 (tr) 2019-06-21
PT3521286T (pt) 2021-12-30
US20220220097A1 (en) 2022-07-14
MX369952B (es) 2019-11-27
US20170037036A1 (en) 2017-02-09
KR20160065950A (ko) 2016-06-09
PT3052492T (pt) 2019-06-27
IL244452B (en) 2020-06-30
AU2014330940B2 (en) 2018-03-15
JP6500017B2 (ja) 2019-04-10
IL244452A0 (en) 2016-04-21
BR112016007329B1 (pt) 2021-02-02
EP3521286A1 (en) 2019-08-07
US9701664B2 (en) 2017-07-11
US10189821B2 (en) 2019-01-29
JP6732071B2 (ja) 2020-07-29
PL3521286T3 (pl) 2022-03-21
CN105814040A (zh) 2016-07-27
US20190106413A1 (en) 2019-04-11
KR102332232B1 (ko) 2021-11-29
US20160289216A1 (en) 2016-10-06
WO2015049535A1 (en) 2015-04-09
AU2014330940A1 (en) 2016-03-03
ES2730705T3 (es) 2019-11-12
HK1224285A1 (zh) 2017-08-18
US11124501B2 (en) 2021-09-21
DK3052492T3 (da) 2019-05-06
GB201317609D0 (en) 2013-11-20
RU2016117056A3 (pt) 2018-05-29
MX2016004114A (es) 2016-06-06
JP2019135234A (ja) 2019-08-15

Similar Documents

Publication Publication Date Title
BR112016007329A2 (pt) composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
PH12015501385A1 (en) Autotaxin inhibitors
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112016011024A2 (pt) Composto, composição farmacêutica, e, usos dos mesmos
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
NZ724907A (en) Quinoxaline derivatives useful as fgfr kinase modulators
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112018011969A2 (pt) compostos heteroaromáticos como inibidores de btk
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018011817A2 (pt) derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
DOP2017000244A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/10/2014, OBSERVADAS AS CONDICOES LEGAIS.